Maximize The Efficiency Of CAR T Cell Functionality Assessment Via Flow Cytometry

In recent years, CAR T cell-mediated immunotherapy has shown clinical efficacy in the fight against cancer. Increased research efforts to address challenges such as poor efficacy and unwanted side effects are required to further advance the field. To investigate specificity, toxicity, and potency of CAR T cells many in vitro assays are used.

However, there are several challenges associated with these assays that limit their use for large-scale screening, for example, loss of sample due to extensive washing steps, laborious planning, sedimentation of cells when acquiring large numbers of samples, low resolution, time-consuming manual steps of plate processing, as well as lack of absolute cell counting.

To improve the quality of potency assay results, we show how Miltenyi Biotec’s flow cytometry solutions can be used for high-throughput and automated in vitro potency assays to screen for CAR T cells’ antigen-specific killing, cytokine-secretion, and phenotype ability with the maximum number of readouts.